Advertisement


Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

2022 ASCO Annual Meeting

Advertisement

Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use such an assay to measure tumor volume, levels of TTMV over the course of treatment, and the association of TTMV to treatment outcomes (Abstract 6006).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
At this meeting, we were pleased to present a translational analysis from NRG Oncology. NRG Oncology is a cooperative group that ran a study called NRG-HN002. This was a study looking for a de-intensification arm for HPV positive oropharyngeal cancer patients to take forward into a phase three setting in HN002. We had two arms on the study, which were a chemo radiation arm to 60 gray with weekly cisplatin, as well as an IMRT alone arm that's delivered over five weeks. This translational study was a study of blood specimens that were taking at three pre-specified endpoints. Baseline prior to treatment, after two weeks of radiation therapy or chemo radiation delivery, and then at two to four weeks after the end of the treatment and the participation rates were actually quite good, even though it was a separate substudy. We had about 50% participation over the course of the study, maybe weighing to about 40% by the end of the study. But half of patients donated specimens and we were able to find a few things with three different hypotheses. First of all, at the pre-treatment baseline, we found that there was a weak to moderate correlation of the detection level of the HPV-DNA fragments, which our tumor tissue modified. A little bit more specific than regular cell-free DNA. We were able to find a weak to moderate correlation with the overall gross tumor burden. We also found that 10% of patients were undetectable at baseline for a variety of potential reasons, which were continued to explore, could be mismatch with true HPV mismatched to P16, could be characteristics of the samples which were collected in a national study, could be characteristics of the infection, whether integrated or not. We'll continue to investigate that. For the intro treatment sample at two weeks, after two weeks of treatment, we did find a variation in changes over the course of the study in patients. There was some heterogeneity in the pattern of DNA response, which was interesting to see, although the vast majority of patients ended up at undetectability by the completion of treatment at the post-treatment final time point, but it was interesting to see that variation and also to see that it wasn't necessarily true of all patients that they had continuous decreases in the fragments per ml. Although if you looked at the median level overall, the trend was downward throughout the course of treatment. And then at the post-treatment time point, what we found was that essentially there seemed to be an association that was statistically significant with PFS events, and that is pretty notable because the patients on this study generally did pretty well. And we had a relatively small number of PFS events, but they were associated with continued detectability by the end of treatment. I think what's important about this study on an operational and sort of national scale is that this was done in a large scale national study within the cooperative group setting. And so it really shows the feasibility of being able to conduct meaningful translational research within that setting. And also it gives us a pathway forward. We have been able to confirm with this study that the level of tumor tissue modified HPV-DNA is appearing to be prognostic for outcome. And the fact that we're able to do in this study moves us towards the ability to standardize and possibly do more meaningful research in the future that moves us towards not just prognostic, but predictive biomarker status and potential implementation and actionability. I want to thank all the patients and investigators who cooperated in this study, it was a great team effort. And thank NRG headquarters, especially operations, biospecimen resource and statistical group for their support.

Related Videos

Gynecologic Cancers

Benoit You, MD, PhD, on Ovarian Cancer: Who Benefits From Bevacizumab in the First-Line Setting

Benoit You, MD, PhD, of Lyon University hospital (HCL, France) and GINECO group (France), discusses findings from the GOG-0218 trial of patients with ovarian cancer, which appears to confirm earlier data on the link between poor tumor chemosensitivity and benefit from concurrent plus maintenance bevacizumab. In Dr. You’s validation study, patients who derived the most progression-free and overall survival benefit from bevacizumab were those with high-risk disease (stage IV or incompletely resected stage III) associated with an unfavorable KELIM score (CA-125 kinetic elimination rate constant, calculable online) (Abstract 5553).

Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination with standard doublet first-line chemotherapy for patients with RAS wild-type and left-sided metastatic colorectal cancer. The study showed that panitumumab improved overall survival in combination with mFOLFOX6, which may establish a standard first-line combination regimen for this population (Abstract LBA1).

Lung Cancer
Immunotherapy

Gilberto de Lima Lopes, Jr, MD, MBA, and Oladimeji Akinboro, MD, MPH, on NSCLC: Outcomes of Anti–PD-(L)1 Therapy With or Without Chemotherapy in the First-Line Setting

Gilberto de Lima Lopes, Jr, MD, MBA, of Sylvester Comprehensive Cancer Center at the University of Miami, and Oladimeji Akinboro, MD, MPH, of the U.S. Food and Drug Administration (FDA), discuss a data analysis, which suggests that most subgroups of patients with advanced non–small cell lung cancer with a PD-L1 score of 50% or greater who are receiving FDA-approved chemotherapy/immunotherapy regimens may have overall survival outcomes comparable to or better than immunotherapy-alone regimens (Abstract 9000).

Breast Cancer
Immunotherapy

Lisa A. Carey, MD, and Shanu Modi, MD, on Breast Cancer: Is T-DXd a Potential New Standard of Care for HER2-Low Disease?

Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discuss the phase III findings from the DESTINY-Breast04 trial, which compared fam-trastuzumab deruxtecan-nxki (T-DXd) vs treatment of physician’s choice (TPC) in patients with HER2-low unresectable and/or metastatic breast cancer. T-DXd is the first HER2-targeted therapy to demonstrate clinically meaningful improvement in progression-free and overall survival compared with TPC in this patient population, regardless of hormone receptor or immunohistochemistry status or prior use of CDK4/6 inhibitors (Abstract LBA3).

Hepatobiliary Cancer
Immunotherapy

Akihiro Ohba, MD, on Biliary Tract Cancer: New Findings on Fam-Trastuzumab Deruxtecan-nxki

Akihiro Ohba, MD, of Japan’s National Cancer Center Hospital, discusses phase II data from the HERB trial on fam-trastuzumab deruxtecan-nxki, which showed activity in patients with HER2-expressing unresectable or recurrent biliary tract cancer (Abstract 4006).

Advertisement

Advertisement




Advertisement